Skip to main content
SpringerLink
Log in

Multiple factors must be considered when selecting the best antidepressant to treat depression in patients with cancer

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Depression can be common in patients with cancer. If it impacts negatively on the patient or aspects of patient care, pharmacological treatment may be warranted. The selection of the antidepressant must be individualized, and take into consideration multiple factors related to the patient, disease and drug therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Torta RGV, Ieraci V. Pharmacological management of depression in patients with cancer: practical considerations. Drugs. 2013;73(11):1131–45.

    Article  CAS  PubMed  Google Scholar 

  2. Torta RGV, Miniotti M, Leombruni P. Antidepressants in oncology: reason and choice. Neuropathol Dis. 2012;1(2):179–204.

    Article  Google Scholar 

  3. Akechi T, Okuyama T, Onishi J, et al. Psychotherapy for depression among incurable cancer patients. Cochrane Database Syst Rev. 2008;(2):CD005537.

  4. Rodin G, Lloyd N, Katz M, et al. The treatment of depression in cancer patients: a systematic review. Support Care Cancer. 2007;15(2):123–36.

    Article  PubMed  Google Scholar 

  5. Iovieno N, Tedeschini E, Ameral VE, et al. Antidepressants for major depressive disorder in patients with a co-morbid axis-III disorder: a meta-analysis of patient characteristics and placebo response rates in randomized controlled trials. Int Clin Psychopharmacol. 2011;26(2):69–74.

    Article  PubMed  Google Scholar 

  6. Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA. 2010;303(1):47–53.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. Torta RG, Munari J. Symptom cluster: depression and pain. Surg Oncol. 2010;19(3):155–9.

    Article  PubMed  Google Scholar 

  8. Gharibian D, Polzin JK, Rho JP. Compliance and persistence of antidepressants versus anticonvulsants in patients with neuropathic pain during the first year of therapy. Clin J Pain. 2013;29(5):377–81.

    Article  PubMed  Google Scholar 

  9. Torta R, Leombruni P, Borio R, et al. Duloxetine for the treatment of mood disorder in cancer patients: a 12-week case-control clinical trial. Hum Psychopharmacol. 2011;26(4–5):291–9.

    Article  CAS  PubMed  Google Scholar 

  10. Senkus E, Jassem J. Cardiovascular effects of systemic cancer treatment. Cancer Treat Rev. 2011;37(4):300–11.

    Article  CAS  PubMed  Google Scholar 

  11. Razavi D, Kormoss N, Collard A, et al. Comparative study of the efficacy and safety of trazodone versus clorazepate in the treatment of adjustment disorders in cancer patients: a pilot study. J Int Med Res. 1999;27(6):264–72.

    CAS  PubMed  Google Scholar 

  12. Davis MP. Does trazodone have a role in palliating symptoms? Support Care Cancer. 2007;15(2):221–4.

    Article  PubMed  Google Scholar 

  13. Grassi L, Biancosino B, Marmai L, et al. Effect of reboxetine on major depressive disorder in breast cancer patients: an open-label study. J Clin Psychiatry. 2004;65(4):515–20.

    Article  CAS  PubMed  Google Scholar 

  14. Bould H, Wiles N, Potokar J, et al. Does baseline fatigue influence treatment response to reboxetine or citalopram in depression? An open label randomized controlled trial. J Psychopharmacol. 2012;26(5):663–6.

    Article  PubMed  Google Scholar 

  15. British Medical Association and the Royal Pharmaceutical Society of Great Britain. British National Formulary (September 2013). London: BMJ Group and the Royal Pharmaceutical Society; 2013.

  16. Pezzella G, Moslinger-Gehmayr R, Contu A. Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitriptyline. Breast Cancer Res Treat. 2001;70(1):1–10.

    Article  CAS  PubMed  Google Scholar 

  17. Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001;344(13):961–6.

    Article  CAS  PubMed  Google Scholar 

  18. Williams S, Dale J. The effectiveness of treatment for depression/depressive symptoms in adults with cancer: a systematic review. Br J Cancer. 2006;94(3):372–90.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  19. Razavi D, Allilaire JF, Smith M, et al. The effect of fluoxetine on anxiety and depression symptoms in cancer patients. Acta Psychiatr Scand. 1996;94(3):205–10.

    Article  CAS  PubMed  Google Scholar 

  20. Torta R, Siri I, Caldera P. Sertraline effectiveness and safety in depressed oncological patients. Support Care Cancer. 2008;16(1):83–91.

    Article  PubMed  Google Scholar 

  21. Adelson KB, Loprinzi CL, Hershman DL. Treatment of hot flushes in breast and prostate cancer. Expert Opin Pharmacother. 2005;6(7):1095–106.

    Article  CAS  PubMed  Google Scholar 

  22. Biglia N, Torta R, Roagna R, et al. Evaluation of low-dose venlafaxine hydrochloride for the therapy of hot flushes in breast cancer survivors. Maturitas. 2005;52(1):78–85.

    Article  CAS  PubMed  Google Scholar 

  23. Papakostas GI, Nutt DJ, Hallett LA, et al. Resolution of sleepiness and fatigue in major depressive disorder: a comparison of bupropion and the selective serotonin reuptake inhibitors. Biol Psychiatry. 2006;60(12):1350–5.

    Article  CAS  PubMed  Google Scholar 

  24. Portela MA, Rubiales AS, Centeno C. The use of psychostimulants in cancer patients. Curr Opin Support Palliat Care. 2011;5(2):164–8.

    Article  PubMed  Google Scholar 

  25. Shibahara H, Ito T, Uematsu N, et al. Low-dose mirtazapine improved nausea and appetite loss during S-1 therapy (in Japanese). Gan To Kagaku Ryoho. 2012;39(1):143–5.

    PubMed  Google Scholar 

  26. Davis MP, Khawam E, Pozuelo L, et al. Management of symptoms associated with advanced cancer: olanzapine and mirtazapine. A World Health Organization project. Expert Rev Anticancer Ther. 2002;2(4):365–76.

    Article  CAS  PubMed  Google Scholar 

  27. Carroll DG, Kelley KW. Use of antidepressants for management of hot flashes. Pharmacotherapy. 2009;29(11):1357–74.

    Article  CAS  PubMed  Google Scholar 

  28. Davis MP, Kirkova J, Lagman R, et al. Intolerance to mirtazapine in advanced cancer (letter). J Pain Symptom Manage. 2011;42(3):e4–7.

    Article  PubMed  Google Scholar 

  29. Torta R, Berra C, Binaschi L, et al. Amisulpride in the short-term treatment of depressive and physical symptoms in cancer patients during chemotherapies. Support Care Cancer. 2007;15(5):539–46.

    Article  PubMed  Google Scholar 

  30. Thachil AF, Mohan R, Bhugra D. The evidence base of complementary and alternative therapies in depression. J Affect Disord. 2007;97(1–3):23–35.

    Article  CAS  PubMed  Google Scholar 

  31. Fava M, Giannelli A, Rapisarda V, et al. Rapidity of onset of the antidepressant effect of parenteral S-adenosyl-l-methionine. Psychiatry Res. 1995;56(3):295–7.

    Article  CAS  PubMed  Google Scholar 

Download references

Disclosure

This article was adapted from Drugs 2013;73(11):1131–45 [1]. The preparation of these articles was not supported by any external funding.

Author information

Authors and Affiliations

    Consortia

    Adis Medical Writers

    Rights and permissions

    Reprints and permissions

    About this article

    Cite this article

    Adis Medical Writers. Multiple factors must be considered when selecting the best antidepressant to treat depression in patients with cancer. Drugs Ther Perspect 30, 55–59 (2014). https://doi.org/10.1007/s40267-013-0096-y

    Download citation

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s40267-013-0096-y

    Keywords

    Search

    Navigation